Dicerna Pharmaceuticals

@DicernaPharma

Delivering RNAi-based breakthrough therapies to improve lives.

Lexington, MA
Vrijeme pridruživanja: ožujak 2012.

Tweetovi

Blokirali ste korisnika/cu @DicernaPharma

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @DicernaPharma

  1. proslijedio/la je Tweet
    2. velj

    At the 2019 Global Genes Patient Advocacy Summit, our RARE Revolution team had the privilege of hosting a roundtable in partnership with Dicerna Pharmaceuticals and the Oxalosis and Hyperoxaluria Foundation. Open:

    Poništi
  2. proslijedio/la je Tweet
    3. velj
    Poništi
  3. 3. velj

    Dicerna and are harnessing Dicerna's GalXC™ technology to develop DCR-HBVS (RG6346) and novel therapies for chronic . Learn more here:

    Poništi
  4. 31. sij

    At Dicerna, we foster a culture of innovation through collaboration. View our list of current opportunities on our careers page:

    Poništi
  5. 30. sij

    Dicerna is developing nedosiran (DCR-PHXC) for the treatment of , for which there are currently no approved treatments. Learn more here:

    Poništi
  6. 23. sij

    Looking to be a part of a dynamic team in ? Visit our careers page to view current opportunities:

    Poništi
  7. proslijedio/la je Tweet
    21. sij

    Join us for the Los Angeles Alpha-1 Education Day on February 29, in conjunction with Rare Disease Day! We invite all Alphas, family members, caregivers, friends, healthcare providers, to attend this day-long event on the latest Alpha-1 topics. Visit

    Poništi
  8. 16. sij

    At Dicerna, to fight disease. To learn more about us, visit our website:

    Poništi
  9. 3. sij

    In the January issue of , Doug Fambrough sheds light on why is an attractive area for research and shares how Dicerna is working toward its goal of providing innovative treatment options to rare and genetic disease communities. Read here:

    Poništi
  10. 2. sij

    Dicerna announced the successful closing of the discovery and development agreement between Dicerna and Novo Nordisk for treatments for liver-related cardio-metabolic diseases. Read more here:

    Poništi
  11. If you're looking to work in , then Dicerna may be a good fit for you. Visit our website for more information on current employment opportunities:

    Poništi
  12. Dicerna announced the successful closing of the research collaboration and licensing agreement between Dicerna and Roche for treatments for chronic hepatitis B virus infection. Read more here:

    Poništi
  13. Primary hyperoxaluria occurs in an estimated 1 in 120,000 live births around the world. It is estimated that more than 5,000 people in the United States and European Union are living with . For more about Dicerna's PHYOX trials, visit:

    Poništi
  14. Approximately 10% of infants with A1AT deficiency develop liver disease, and about 15% of adults with A1AT deficiency develop cirrhosis. Learn more about our A1AT program here:

    Poništi
  15. Dicerna receives orphan drug designation from the European Commission for DCR-A1AT for the treatment of congenital alpha-1 antitrypsin (A1AT) deficiency. Read more here

    Poništi
  16. Dicerna and Alexion announced that Alexion exercised its option for exclusive rights to two additional targets within the complement pathway for the discovery and development of GalXC™ RNAi molecules. Learn more here

    Poništi
  17. proslijedio/la je Tweet
    16. pro 2019.

    in Dubai! For the third time and @rarediseasedaydubai are organising a walk and kite flying for Rare Disease Day 2020! Head to to find out what events are taking place in your country for Rare Disease Day 2020!

    Poništi
  18. proslijedio/la je Tweet

    Today we announced an extension of our collaboration with .

    Poništi
  19. To learn more about Dicerna's DCR-HBVS, a GalXC RNAi platform-based product candidate for the treatment of chronic , please visit:

    Poništi
  20. If you or someone you know has , visit our website to learn more about Dicerna's PHYOX clinical trials:

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·